预约演示
更新于：2025-10-09
Cromolyn Sodium
色甘酸钠
更新于：2025-10-09
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 爱尔兰 (1980-11-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C23H16Na2O11 |
InChIKeyAIXRIMKZFKFIAF-UHFFFAOYSA-N |
CAS号15826-37-6 |
关联
32
项与 色甘酸钠 相关的临床试验NCT07142291
A Phase IIB Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1A (Cromolyn) as an Adjuvant Treatment in Subjects With Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)
NCT03202147
A Phase II Safety and Efficacy Study of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)
NCT05076682
Reverse Triple Negative Immune Resistant Breast Cancer
100 项与 色甘酸钠 相关的临床结果
登录后查看更多信息
100 项与 色甘酸钠 相关的转化医学
登录后查看更多信息
100 项与 色甘酸钠 相关的专利（医药）
登录后查看更多信息
4,190
项与 色甘酸钠 相关的文献（医药）2025-09-09CHEMICAL RECORD
Harnessing Chromone as a Versatile Scaffold for Emerging Biological Applications: Recent Advances and Medicinal Insights.
Review
作者: Gogoi, Neelutpal ; Dutta, Debashis ; Kaishap, Partha Pratim ; Laskar, Boonam ; Dey, Tapan
Chromones, characterized by a benzo-annulated γ-pyrone core, represent a privileged scaffold, offering a diverse pharmacological spectrum. Clinically approved drugs such as disodium cromoglycate and flavoxate underscore their therapeutic significance. Recent advancements in synthetic strategies have facilitated the development of novel chromone derivatives with improved bioactivity, selectively modulating key molecular targets implicated in cancer, inflammation, diabetes, infectious diseases, and neurodegenerative disorders. Furthermore, their emerging utility as imaging probes and regulators of pharmacologically relevant targets, such as pyridoxal phosphatase (PDXP), highlights their expanding role in modern drug discovery. This review provides a comprehensive overview of recent progress in the identification of bioactive chromone-based natural products and synthetic analogs, emphasizing their therapeutic potential. Additionally, critical innovations in recent synthetic methodologies and targeted therapeutic applications are discussed, reinforcing chromones as a sustainable and multifunctional framework for next-generation drug development.
2025-09-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Network and pharmacophore guided and BCL2 and HSP90AA1 targeted drug repurposable approaches against rheumatoid arthritis mediated diffuse large B-cell lymphoma
Article
作者: Islam, K M Tanjida ; Shibly, Abu Zaffar
Rheumatoid arthritis (RA) raises the incidence of Diffuse large B-cell lymphoma (DLBCL) development, presenting a critical clinical challenge due to the intersection of autoimmunity and malignancy. However, molecular mechanisms underlying RA-mediated DLBCL progression and therapeutic interventions remain poorly elucidated. To address this gap, we developed a novel GCNConv deep learning pipeline to predict key molecular hubs within shared genes of RA and DLBCL networks and validated them through literature mining. Network and pharmacophore-guided virtual screening evaluated 804 off-patent FDA-approved medications for therapeutic repurposing potential against identified hub targets. Our analysis revealed 86 dysregulated genes common to both conditions, with BCL2 and HSP90AA1 emerging as the most significant hubs, demonstrating deep learning scores of 0.766 and 0.748, respectively. The GCNConv model exhibited exceptional predictive performance with R2 values of 0.9480, 0.9288, and 0.9117 for training, validation, and test datasets. Pharmacophore-based screening revealed lapatinib and itraconazole as superior BCL2 inhibitors [-7.621 and -7.075] kcal/mol compared to FDA-approved venetoclax [-6.546] kcal/mol, while voriconazole and regadenoson demonstrated robust HSP90AA1 binding [-7.279 and -7.268] kcal/mol, outperforming FDA-approved cromolyn [-5.304] kcal/mol. These findings establish BCL2 and HSP90AA1 as promising dual-purpose therapeutic targets, providing a foundation for addressing both RA management and RA-mediated DLBCL prevention.
2025-08-01BMJ Case Reports
Mastocytic enterocolitis in a patient with chronic diarrhoea
Article
作者: Tseng, Serena ; Pathria, Mohini
This is a case of mastocytic enterocolitis in a patient with a longstanding history of suspected diarrhoea-predominant irritable bowel syndrome (IBS-D).A female patient in her 60s presents with a history of frequent diarrhoea with faecal urgency for several years. She underwent colonoscopy with gastrointestinal biopsies and immunohistochemical staining for CD117, demonstrating mast cell infiltration. The patient was diagnosed with mastocytic enterocolitis as she did not have symptoms or other findings suggesting systemic mastocytosis. Management with cromolyn sodium prior to meals was ineffective. Alternatively, management with H1 and H2 antihistamines and prebiotics provided significant clinical symptom improvement. In patients with refractory IBS-D, biopsies with immunohistochemical staining for mast cells should be considered. Prebiotic and probiotic supplementation, separately or combined, should also be considered and has not been previously described in the management of mastocytic enterocolitis.
100 项与 色甘酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 春季角膜结膜炎 | 澳大利亚 | 2014-03-04 | |
| 食物过敏 | 英国 | 2005-05-01 | |
| 变应性结膜炎 | 中国 | 1990-01-01 | |
| 哮喘 | 爱尔兰 | 1980-11-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阿尔茨海默症 | 临床3期 | 美国 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 澳大利亚 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 保加利亚 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 加拿大 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 捷克 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 匈牙利 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 波兰 | 2015-09-15 | |
| 缺血性卒中 | 临床2期 | - | 2023-12-01 | |
| 肌萎缩侧索硬化 | 临床2期 | 美国 | 2020-09-08 | |
| 银屑病 | 临床2期 | 德国 | 2012-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 1 | 夢獵鏇蓋鹽觸襯選顧選 = 憲淵願鬱窪糧蓋廠窪觸 簾憲遞窪膚壓窪製膚願 (鹽糧鬱餘壓選鑰襯築築, 繭憲糧獵鹹鬱鬱廠繭淵 ~ 艱繭膚膚築願觸選艱壓) 更多 | - | 2024-04-25 | |||
临床4期 | 16 | (Oral Cromolyn) | 餘構蓋鏇網製廠淵願壓(遞淵鏇淵餘製選鹹蓋網) = 蓋廠壓鑰範顧願醖醖網 窪壓壓鹽網窪願遞繭積 (壓顧蓋齋顧壓鹹鬱鹹壓, 44.02) 更多 | - | 2023-10-26 | ||
Placebo (Placebo) | 餘構蓋鏇網製廠淵願壓(遞淵鏇淵餘製選鹹蓋網) = 醖鹹願願遞醖鹽繭壓獵 窪壓壓鹽網窪願遞繭積 (壓顧蓋齋顧壓鹹鬱鹹壓, 52.7) 更多 | ||||||
临床1/2期 | 10 | (Cromolyn) | 廠壓衊遞淵齋製蓋糧醖(製憲遞範膚遞淵構築鹹) = 網鹽遞夢廠遞鑰窪淵獵 遞鏇糧遞觸顧廠製衊獵 (夢膚網網糧簾衊醖衊蓋, 1.9) 更多 | - | 2019-07-30 | ||
(Vehicle) | 廠壓衊遞淵齋製蓋糧醖(製憲遞範膚遞淵構築鹹) = 醖網餘艱鬱觸憲膚築願 遞鏇糧遞觸顧廠製衊獵 (夢膚網網糧簾衊醖衊蓋, 1.4) 更多 | ||||||
临床4期 | - | Viscous oral cromolyn sodium 100mg | 艱獵網獵構簾鹹餘築夢(顧鹹憲鏇繭淵襯壓夢積) = 選獵簾糧顧遞蓋鬱餘齋 製選觸製積製衊糧願壓 (膚襯糧鬱鑰淵繭餘憲壓 ) | - | 2018-05-01 | ||
Viscous oral cromolyn sodium 200mg | 遞艱製構積膚觸鏇構鏇(簾齋簾網窪範簾齋憲製) = 觸糧顧齋鹽壓廠鹹繭觸 構鹽淵鏇廠網壓觸觸簾 (獵範壓繭獵繭顧選窪艱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用